To read all of these articles and more, visit centerforbiosimilars.com.

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...

Malcolm Qualie, pharmacy lead, specialised services at NHS England, says incentives to switch to biosimilars could help reduce the pressure on NHS budgets. Speaking in London at the Ethical ...

Switching between infliximab biosimilar SB2 and the reference product ... According to the investigators, “the initial and the reverse switch had no relevant impact on the course of disease ...

The FDA has approved Stoboclo (denosumab-bmwo), a biosimilar to Prolia (denosumab), and Osenvelt (denosumab-bmwo), a biosimilar to Xgeva (denosumab).

Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed ...

Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 ...

Patients who received the biosimilar in the first period continued to do so at week 52; those who received Prolia were randomly assigned to continue the treatment or switch to the biosimilar ...

Patients who have been on Inflectra can continue their therapy without any need to switch between different biosimilars, ensuring consistency in their care during this transition.” Celltrion ...